It seems still a challenging and complex process to overcome sorafenib resistance and the inhibition of Bcl-2 proteins; however, new clinical trial studies are needed as potential alternatives for sorafenib therapy especially for patients with an advanced stage HCC. The gene discussed is BCL2; the disease is hepatocellular carcinoma.